Phase III Randomized Adjuvant Study of MK-3475 (Pembrolizumab) in Muscle Invasive and Locally Advanced Urothelial Carcinoma (AMBASSADOR) Versus Observation
Phase of Trial: Phase III
Latest Information Update: 07 Dec 2019
Price : $35 *
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Bladder cancer; Carcinoma; Urogenital cancer
- Focus Therapeutic Use
- Acronyms AMBASSADOR
- 08 Apr 2019 Planned End Date changed from 28 Feb 2019 to 1 Jun 2025.
- 08 Apr 2019 Planned primary completion date changed from 28 Feb 2019 to 1 Jun 2025.
- 16 Feb 2019 Trial design presented at the 2019 Genitourinary Cancers Symposium.